Cy­cle­ri­on ax­es an­oth­er pro­gram as strug­gles grow for Pe­ter Hecht's Iron­wood spin­out

Things have not been go­ing well in the old Iron­wood pipeline.

Last month, the Boston-based phar­ma­ceu­ti­cal com­pa­ny an­nounced that the sec­ond of just two ex­per­i­men­tal drugs they had left in the pipeline failed a Phase III tri­al, trig­ger­ing sig­nif­i­cant lay­offs. And to­day, their Pe­ter Hecht-led R&D-fo­cused spin­off, Cy­cle­ri­on, an­nounced that it had al­so failed their sec­ond ma­jor study in a year, forc­ing them to aban­don the pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER